Contract Manufacturing, General

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

Biomanufacturing capacity expansion uses modular cleanroom design and single-use technologies.

Outsourcing is taking on a greater role in the biopharmaceutical manufacturing industry.

European CDMOs want into the US market, but entry options are limited.

The trend of exits from the CMO industry looks to be gaining momentum.

With budgets growing, clients see CMOs' costs as less crucial.

Evolving clinical trial research services give biopharmaceutical companies options for full- and functional-services.

The CMO industry's value proposition is limiting its market penetration.

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Changes in company ownership shake up the CMO industry.

Ongoing changes create new opportunities for CROs and CMOs.

Are strategic partnerships in clinical research a model for CMC services?

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Outsourcing is weighing in more as a tactic for cost-cutting, but it is still not the primary weapon.

An innovative approach to capacity management.

Successful management of the CMO/client relationship should include open communication and trust.

BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing.

Will international biomanufacturing outsourcing become mainstream in this decade?

Measuring the size of the market for contract manufacturing services requires a careful hand.

Industry wants more innovation, but can suppliers meet customers' needs?

The evolving bio/pharmaceutical business model poses risk for CMOs.

Industry optimism is on the rise for 2012.

A Q&A with Rick Hancock, president of Althea Technologies. This article contains bonus online material.

A survey provides insight into drug companies' plans for spending on outsourced services. This article contains bonus online material.

Insights from real-time ranking of global biomanufacturing capabilities.

Incorporating regulatory requirements into the product life cycle is crucial.

Knowing where key biomanufacturing facilities are located around the world is essential for decision-making.

Clear documentation and open communication are essential for effective technology transfer.

Rapid microbial screening provided by contract laboratories can save companies time and money.

The authors present lessons learned from a case study of the transfer of a cell culture biotherapeutic process to a CMO.